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PENYARINGAN PENGKOMPUTERAN DAN KAJIAN IN VITRO 
TUMBUHAN MALAYSIA UNTUK SIFAT-SIFAT ANTI OBESITI 
MENSASARKAN LIPASE PANKREAS 
ABSTRAK 
Lipase pankreas ialah enzim yang bertanggungjawab dalam pencernaan 
lemak diet kepada asid lemak bebas dan monoasilgliserol. Pengambilan lemak diet 
yang tinggi akan menyebabkan pengumpulan lemak berlebihan dalam badan dan 
seterusnya menyebabkan pertambahan berat badan dan obesiti. Obesiti telah 
menyebabkan masalah ekonomi dan kesihatan di Malaysia dan juga seluruh dunia. 
Untuk mencari alternatif bagi agen anti-obesiti, kaedah penyaringan in siliko dan in 
vitro digunakan dengan mensasarkan lipase pankreas untuk menghalang pencernaan 
lemak diet. Saringan in siliko dilakukan dengan menggunakan 3963 sebatian 
fitokimia dari pangkalan data NADI, di mana pendokan terhadap lipase pankreas 
(PDB ID: 1LPB) dilakukan. Daripada keputusan penyaringan, 13 tumbuhan dengan 
sebatian teratas telah dikenalpasti sebagai Momordica charantia, Jatropha curcas, 
Endiandra kingiana, Calophyllum inophyllum, Garcinia mangostana, Chisocheton 
ceramicus, Aglaia argentea, Artocarpus champeden, Manilkara zapota, Dysoxylum 
hainanense, Capsicum annum, Oryza sativa dan Hopea hainanensis. Ekstrak 
metanolik mentah tumbuhan terpilih ini telah diuji untuk kajian in vitro bagi 
menyiasat aktiviti perencatan terhadap lipase pankreas. Daripada penilaian in vitro, 
ekstrak metanolik Manilkara zapota dikenal pasti sebagai perencat yang berpotensi 
untuk lipase pankreas dengan 92.5 % perencatan, diikuti oleh Oryza sativa (77.7 %), 
Garcinia mangostana (60.0 %), Endiandra kingiana (58.0 %) dan Momordica 
charantia (13.3 %). Penilaian pendokan Manilkara zapota telah dinilai dan didapati 
xiii 
sebatioan yang diramalkan dengan sifat anti lipase adalah dari kumpulan terpene. 
Dengan menggunakan teknik bioassai terpandu, Manilkara zapota disekatkan kepada 
fraksi n-heksana, etil asetat dan air. Fraksi n-heksana menunjukkan 90.0 % 
perencatan terhadap lipase pankreas seterusnya dipecahkan menggunakan 
kromatografi turus. Selepas langkah pemecahan, daripada 14 pecahan yang 
terkumpul, 10 pecahan menunjukkan aktiviti perencatan melebihi 70.0 %. Pecahan 
ditandakan sebagai Fr1 yang memberi 90.8 % perencatan, diikuti oleh Fr2 (94.1 %), 
Fr3 (94.7 %), Fr4 (91.6 %), Fr5 (90.7 %), Fr8 (92.4 %), Fr10 (89.9 %), Fr14 (92.9 
%), Fr15 (70.4 %) dan Fr16 (85.8 %). Pecahan-pecahan aktif yang diperolehi 
daripada Manilkara zapota adalah berpotensi dipencilkan sebatian aktifnya untuk 
diuji sebagai agen anti-lipase. 
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COMPUTATIONAL SCREENING AND IN VITRO STUDY OF MALAYSIAN 
PLANTS FOR ANTI OBESITY PROPERTIES TARGETING  
PANCREATIC LIPASE  
ABSTRACT 
Pancreatic lipase is the enzyme responsible for hydrolysis of dietary fats to 
free fatty acids and monoacylglycerol. High intake of dietary fats will cause excess 
accumulation of fat in the body and will further cause overweight and obesity. In 
order to find alternatives for anti-obesity agents, in silico screening and in vitro 
methods were employed, targeting pancreatic lipase to restrain hydrolysis of dietary 
fat. In silico screening was first done using 3963 phytochemical compounds from 
NADI database, which were docked onto pancreatic lipase (PDB ID: 1LPB). From 
the screening results, 13 plants with top hits compounds were identified namely,  
Momordica charantia, Jatropha curcas, Endiandra kingiana, Calophyllum 
inophyllum, Garcinia mangostana, Chisocheton ceramicus, Aglaia argentea, 
Artocarpus champeden, Manilkara zapota, Dysoxylum hainanense, Capsicum 
annum, Oryza sativa and Hopea hainanensis. The crude methanolic extracts of these 
selected plants were tested for in vitro study to investigate inhibition activity against 
pancreatic lipase. From in vitro assessment, the methanolic extract of Manilkara 
zapota was recognized as potential inhibitor for pancreatic lipase with 92.5 % 
inhibition, followed by Oryza sativa (77.7 %), Garcinia mangostana (60 %), 
Endiandra kingiana (58 %) and Momordica charantia (13.3 %). Docking assessment 
of Manilkara zapota was evaluated to discover the predicted compounds with anti 
lipase properties are from terpene group. Using bioassay guided technique, the 
extract of Manilkara zapota was partitioned into n-hexane, ethyl acetate and water 
xv 
 
fractions. The n-hexane fraction which showed 90.0 % of inhibition against 
pancreatic lipase was further fractionated using column chromatography. After 
fractionation step, out of 14 fractions collected, 10 fractions showed inhibitory 
activity of more than 70.0 %. The fraction assigned as Fr1 exhibited 90.8 % of 
inhibition, followed by Fr2 (94.1 %), Fr3 (94.7 %), Fr4 (91.6 %), Fr5 (90.7 %), Fr8 
(92.4 %), Fr10 (89.9 %), Fr14 (92.9 %), Fr15 (70.4 %) and Fr16 (85.8 %). The active 
fractions that were derived from Manilkara zapota could potentially be isolated for 







Obesity is an emerging global health burden, in developed and developing 
countries, despite their income levels (Oxfam, 2014). Obesity has been declared as 
global epidemic since 1997 by World Health Organization (WHO), affecting both 
adults and children (Oxfam, 2014). If this situation is not well control, the involved 
countries may have to deal with emerging challenges, for examples, increase in 
healthcare spending, increase in number of related diseases resulting from obesity 
and lost of productive years. 
 
1.2 Statement of problem 
Obesity prevalence is increasing because of various factors such as 
urbanization, economic quality, lifestyles and genetic factors (Hruby and Hu, 2015). 
Since the last three decades, rate of obesity in Asia has increased by more than 
doubled. From 1980 to 2013, the percentage of adults having Body Mass Index 
(BMI) at or more than 25 kg/m2 had increased by 8.1 % in men and 8.2 % in women 
(The Economist, 2017). Table 1.1 shows the increment percentage of obese adults 
from 2010 to 2014 (The Economist, 2017). In four years, the number of obese people 
has increased up to more than 30 % in ASEAN countries. These numbers are 
increasing at alarming rate and have become a major concern in Malaysia. A 
research by Oxfam International, released on January 2014, revealed that Malaysian 
has become the fattest population in Southeast Asia. The research carried out by the 
United Kingdom Poverty And Disaster Relief Group has ranked Malaysia in 44th 
place in a list of 125 countries (Oxfam, 2014). In 2015, another survey by World 
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Obesity Federation (http://www.worldobesity.org/) conducted in Malaysia reported 
that 15% of men age 18 and above were obese. While, for women, 20.6% age 18 and 
above were obese. It is also estimated that there will be 2.16 billion overweight 
people and 1.12 billion obese people with concurrent to other diseases (Segheto et. 
al., 2015). 
Table 1.1: Percentage of obese adults and their increment on selected countries. 
Data is taken from The Economist report (2017). 
 
Current treatments given to obese patients are medication, controlled diet and 
exercise (Mahgerefteh et. al., 2013). Orlistat (1) and sibutramine (2) are examples of 
authorized drugs for obesity treatment (Figure 1.2). However, these drugs give 
negative side effects upon administration. Patients will experience nausea, 
drowsiness, severe pain in lower back and upper stomach and increased number of 
bowel movement after taking orlistat (1)  (Dourish et. al., 2008). Sibutramine (2) 
cause patients to experience dry mouth, increase blood pressure, constipation and 
tachycardia (Dourish et. al., 2008). Controlled diet and physical activity to increase 
energy expenditure approaches, were only able to give promising effect in a short 
period of time. Obese patients appeared to gain weight after sometimes upon taking 
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these clinical treatments (de la Garza et. al., 2011). Hence, scientist is looking for 
different approaches and initiatives to treat obesity by targeting natural products.  
 
Besides increasing prevalence of obesity and side effects of current 
treatments, Malaysia and related countries have to allocate a lot of money for 
healthcare expenses and clinical researches with the risk that the researches being 
halted due to negative outcomes (The Economist, 2017). Current treatments and 
improvement measures taken to improve health had cost Malaysia more than RM4 
billion according to a survey by The Economist newspaper. Some studies conducted 
in a few countries showed that an obese person acquired higher cost for healthcare by 
more than 25% compared to a healthy person. Considering these factors, it is vital to 
find other treatments or new drugs by exploiting natural sources to find potential 
inhibitor to treat obesity (The Economist, 2017).  
 
1.3 Objectives of the study 
The objectives of the study are: 
1. To investigate potential anti-obesity agents targeted pancreatic lipase from  
native plants in Malaysia using computational approach.  
2. To understand the binding interaction of bioactive compounds with 
pancreatic lipase. 
3. To apply bioassay guided approach in order to identify the active  
extracts, fractions and sub-fractions.  
4. To perform in vitro pancreatic lipase assay and investigate the  





LITERATURE REVIEW  
2.1 Obesity 
2.1.1 Overview about obesity 
Obesity has become a major health problem not only in Malaysia, but also 
worldwide affecting mostly adolescents and adults. Obesity is defined as the excess 
accumulation of fat in the body which exceeding the required amount needed by the 
body that may impair health. This is caused by imbalance between energy intake and 
energy expenditure (Roh and Jung, 2012). A report from Royal College of 
Physicians of London, stated obesity as body mass index (BMI) exceeding 30 kg/m2, 
whereas overweight is stated as BMI between 25 kg/m2 and 29.9 kg/m2 (Nguyen and 
El-Serag, 2010).  Epidemiology studies stated that increasing degrees of overweight 
and obesity is a crucial prognostic of decreased longevity (Anti-Obesity Drugs 
Report, 2003). 
 
A campaign by National Institute of Health (NIH) was done to raise 
awareness about obesity because it is often considered as cosmetic problem by the 
society, rather than health problem (Puhl and Heuer, 2010). Lack of understanding 
about obesity and associated healthcare problems had caused this issue to be seldom 
ignored. Obesity is associated to many diseases such as sleep apnea, coronary heart 
disease, endocrine and metabolic disturbances, cancer, diabetes mellitus, 
hypertension as well as psychological problems (Kazemipoor et al., 2012). It is also 
associated to multidimensional impairments in health-related quality of life and 
psychosocial well-being (Arterburn et. al., 2005). In previous years, researchers have 
spent a lot of money for the treatment and also for the loss of the productivity. There 
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are few ways of treating obesity that involve combination of medication, behavioral 
and dietary modification, pharmacotherapy, exercise and gastric bypass surgery in 
utmost cases (Maria and Evagelia, 2009). Despite all the efforts and remedies 
provided by diet industry, they failed to give long term effect of weight loss for 
obese or overweight people. Individuals who are changing their diet to lose weight 
were estimated to return to their original weight within two to five years (Nelson-
Dooley et. al., 2005). 
 
2.1.2 Obesity in Malaysia 
Economist Intelligence Unit (EIU) from The Economist newspaper has 
conducted a survey and research in 2017 to study the prevalence of obesity in 
ASEAN countries, which covered Malaysia, Singapore, Indonesia, Thailand, 
Philippine and Vietnam (The Economist, 2017). The results were compiled in a 
report entitled “Tackling Obesity in ASEAN”. Among ASEAN countries, Malaysia 
has the highest obesity prevalence in Southeast Asia with 13.3 % of obese people 
while overweight people were recorded at 38.5 %. Besides the highest prevalence of 
obesity, the condition had cost Malaysia between RM4.26 billion and RM8.53 billion 
for healthcare spending from the previous years. This is equivalent to 9.57 % to 
19.36 % of Malaysia’s healthcare spending (Figure 2.1). Malaysia had the largest 
number of productive years lost among females between seven and twelve years and 
second highest among males in between six and eleven years in ASEAN (The 
Economist, 2017).The reduction in productive years is the impact from affliction 
related to obesity. Increment in obesity statistics at alarming rate appeared 
significantly by lack of exercise and Malaysian eating habit. The report showed that 
only a third of Malaysian adults had ever exercised while only 14 % exercise 
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adequately. Other than that, Malaysian has strong culture of entertaining guests with 
food and often consumes unhealthy diet such as fast foods. Apart from that, 
Malaysian view obesity as cosmetic issue rather than a health issue. 
 
Figure 2.1: Percentage of total cost in healthcare spending according to ASEAN 
countries (The Economist, 2017).  
 
2.1.3 Strategies and treatment of obesity 
There are six strategies to treat obesity that involve different approaches 
summarized by Yun (2010). The available treatments of obesity that have been 
studied are lipase inhibitory, suppression of food intake, stimulating energy 
expenditure, inhibition of adipocyte differentiation, regulation of lipid metabolism 
and also combine effect of the treatments (Yun, 2010).  
 
Lipase inhibitory effect is one of the promising treatments for obesity because 
there is no alteration of central mechanism (Birari and Bhutani, 2007). Pancreatic 
lipase hydrolyzes dietary fat before being absorbed by the intestine. Therefore, 
pancreatic lipase has been widely studied in order to determine its potential as anti-
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obesity agents. Inhibition of pancreatic lipase restrained the dietary fat from being 
hydrolysed and absorbed into the intestine and then excreted as faeces (Godoy-Matos 
et. al., 2011). Phytochemicals that have inhibitory effect on pancreatic lipase are 
polyphenols, saponins, flavonoids and caffeines, which can be found in various type 
of tea leaves and other natural source (Kim and Kang, 2005; Han et. al., 2006 and 
Shimoda et. al., 2006). 
 
Second strategy is suppression of food intake to regulate body weight which 
is related to hormonal and neurological systems (Yun, 2010).  There are few 
receptors in the central nervous system that responsible in satiety regulation such as 
serotonin, dopamine, histamine and other associated receptors. Researches will target 
these receptors in order to treat obesity by reducing energy intake (Chantre and 
Lairon, 2002). Sibutramine is the new drug in the market that can treat obesity via 
appetite suppression. However, sibutramine have known side effects such as 
insomnia, dry mouth and constipation (Chaput et. al., 2007). Garcinia cambogia, 
Korean red ginseng (Kim et. al., 2005), Camellia sinensis (Kao et. al., 2000), 
sunflower oil (Ferrer-Lorente et. al., 2007) and Citrus aurantium (Klontz et. al., 
2006) are few examples of plant that have appetite suppressing properties. These 
plants mainly contain of glycosides, saponins and flavonoids. 
 
Third strategy of treating obesity is by stimulating energy expenditure (Yun, 
2010).  Evidence showed that many rodent models have become obese due to low 
energy expenditure. A mammalian will dissipate excess energy as heat to modulate 
energy expenditure and body weight. Hence, the key in this strategy is to increase 
energy expenditure by physical activity, obligatory energy expenditure or by 
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adaptive thermogenesis (Flatt, 2007). Extracts of Pinellia ternate (Kim et. al., 2006), 
Panax ginseng (Attele et. al., 2002) and Ilex paraguariensis (Pang et. al., 2008) are 
examples of plants that were proven to increase energy expenditure. 
 
The fourth strategy is inhibition on adipocytes differentiation. The main role 
of adipocytes is storing triglycerides and release free fatty acids upon energy demand 
by the body which is important in maintaining energy balance and lipid homeostasis 
in the body (Yun, 2010). Hence, the processes of adipocyte proliferation and 
differentiation are targeted in anti-obesity material screening. However, a research by 
Lefterova and Lazar (2009) exposed that the inhibition of adipogenesis caused 
astherosclerosis and diabetes type 2. Bioactive compounds that are proven to inhibit 
adipocyte differentiation are sporamin from Ipomoea batatas that showed 84 % 
inhibition activity onto preadipocyte differentiation (Xiong et. al., 2009). Mycelia 
extract from Cordyceps militaris decreased lipid accumulation by 93.7 % (Shimada 
et. al., 2008) while ternatin from Coriolus versicolor decreased triglyceride 
accumulation by 87 % (Ito et. al., 2009). 
 
The fifth strategy is regulation on lipid metabolism by prompting triglyceride 
hydrolysis to decrease fat store in the body (Yun, 2010). Various flavonoids 
identified in the extract of Nelumbo nucifera were proven to suppress body weight 
gain in mice (Ohkoshi et. al., 2007).  
 
The sixth strategy is the combination effect of strategies mentioned above 
(Yun, 2009). Catechins from green tea have showed anti-obesity effect by increasing 
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energy expenditure and lipolytic activity, lowering adipocyte differentiation and 
lipogenic activity and suppress appetite (Boschmann and Thielecke, 2007).  
 
2.1.4 Commercial drugs and their side effects 
There are many authorized drugs for the treatment of obesity available in the 
market. Intake of prescribed medicine should be combined with changes in eating 
and physical activity which can help people lose weight by less than 10% of their 
body weight. However, some drugs for obesity treatment may be linked to serious 
health problem.  
 
There are several synthetic drugs that have been used for obesity treatment 
which are orlistat (1), sibutramine (2), lorcaserin (3), rimonabant (4), phentermine (5) 
and topiramate (6) (Figure 2.2), naltrexone/bupropion, and liraglutide,. However, 
sibutramine and rimonabant were withdrawn from market because of their harmful 
side effects (Gadde et. al., 2018). 
 
Orlistat (1), or also known as Xenical® has been available since 1999. The 
substance tetrahydrolipstatin (THL) derived from lipstatin produced by Streptomyces 
toxytricini, appears to be a general inhibitor for mammalian lipases (Lookene et. al., 
1994). Orlistat is approved for adolescent age 12 years and above (Rogovik and 
Goldman, 2011). This drug acts by blocking the digestion of about 30% of dietary fat 
ingested within the lumen of gastrointestinal tract (Dourish et. al., 2008). Orlistat 
does not get absorbed by the body and it only acted inside of the intestine (Moreno 
et. al., 2003). From medical records, individual can lose about 5 to 7 pounds after 
maximum two years of consumption. However, orlistat can give side effects such as 
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diarrhea, gas, stomach pain and rare cases of severe liver injury (Mohamed et. al., 
2014). 
 
Lorcaserin (3), sold as Belviq® is an appetite suppressant drug. It acts on 
serotonin receptors in the brain which causes reduction of energy intake. Consumer 
will feel full after taking small amounts of food. The effectiveness of the drug is 
proven by loss of 5% of initial body weight in one year. However, there are known 
side effects of lorcaserin such as constipation, dry mouth, cough, tiredness, nausea 
dizziness and headaches (Kim et. al., 2014). 
 
Phentermine-topiramate or its commercial name, Qsymia®, is also an appetite 
suppressant drug. Phentermine (5) will suppress appetite, while topiramate, (6) an 
approved drug use to treat epilepsy, have distinct weight loss side effect. The side 
effects due to these combination drugs are constipation, dry mouth, insomnia, 
dizziness, taste alterations and tingling of hands and feet. Phentermine, 
benzphetamine, diethylpropion and phendimetrazine are drugs that sold under many 
names are also appetite suppressant drug (Kim et. al., 2014 and Hendricks, 2017). 
 
Naltrexone/bupropion or its commercial name, Contrave, acts by suppressing 
food intake. Effects from consuming this drug are dizziness, headache, insomnia, 
vomiting, dry mouth and diarrhea. Liraglutide also suppress food intake by decrease 
appetite and increases the feeling of fullness over effects on central nervous system 




Sibutramine (2) sold as Meridia® inhibits re-uptake of serotonin and 
norephinephrine to cause reduction in food intake. Obese people whom consume this 
drug will commonly experience constipation, dry mouth, headache and insomnia. 
There are also possibilities for stroke and heart attack when taking this drug in long 
term period (Mohamed et. al., 2014). Rimonabant (4) or Acomplia® also acted by 
reducing food intake by blocking the cannabinoid-1 receptor. Common side effects 
are dizziness, diarrhea and nausea (Lunagariya et. al., 2014). Both sibutramine and 
rimonabant have been withdrawn from the market because of their serious side 
effects. Sibutramine can lead to heart attack and stroke in high risk cardiac patients. 
Rimonabant can cause probable serious psychiatric disorder (Ado et. al., 2013).  
 
Figure 2.2: Chemical structure of orlistat (1), sibutramine (2), lorcaserin (3), 




2.2 Lipid digestion and absorption  
Obesity is a multifactorial and heterogeneous syndrome affected from 
environmental factors and genetic susceptibility. The environmental factors are 
mainly due to daily diet and lifestyle (Brettfeld et al., 2015 and Nirmala et. al., 
2008).  Iqbal and Hussain (2009), reported that triglyceride (TAG) is the most 
abundant type of lipid complexes found in food that give about 90-95 % of total 
energy attained from dietary fats. Digestion of TAG begins in the mouth and 
stomach by the action of lipase and continued in the small intestine. Less than 30 % 
of dietary lipids are digested in the mouth and stomach. Major hydrolysis of TAG 
happened in small intestine by the action of pancreatic lipase. Lipid digestion in 
small intestines occurs in systemic manner involving bile salts and pancreatic lipase 
(Iqbal and Hussain, 2009). Lipids will be delivered to the intestinal lumen as crude 
lipid emulsion particle. Most dietary fats exist as emulsion to permit transportation 
throughout the water-rich environment in the body because lipids are hydrophobic in 
nature. In the presences of lipid emulsion, bile salts are released into lumen to help 
the formation of micelles. Meanwhile, pancreatic lipase coheres to the lipid emulsion 
and hydrolyzed the ester bond of the TAG to produce free fatty acid and 
monoacylglycerol. After the hydrolysis process, micelles with phospholipids in 
vesicles are formed. Micelles are water soluble lipid materials that contain bile salts. 
This allows lipid substances to be transported in aqueous environment and absorbed 
into enterocyte (Lunagariya et. al., 2014). Inside enterocytes, the hydrolysis product 
of TAG will undergo biosynthesis process of TAG. Lipids would be then stored in 
the body in the form of TAG (Kerr et. al., 2015).  The process of lipid digestion and 




Fat-rich diet will cause excess TAG in the body. Digested dietary triglyceride 
which hydrolyzed to fatty acid and glycerol are absorbed by small intestine. Excess 
triglyceride in the body will accumulate in the adipose tissue causing obesity 
(Schwartz and Wolins, 2007 and Ahmadian et al., 2007). As the result from the 
lipase absences or the lipase inhibition, dietary fats are not hydrolyzed and being 
excreted through stools.  This causes reduced weight or slow growth, loss of fluids 





Figure 2.3: Mechanism of dietary lipid digestion and absorption. A mixture of 
fat droplets binds with cholesterols and bile salts to form micelle. Hydrolysis by 
lipase results into free fatty acids and will be absorbed into enterocyte and 








2.3 Natural products as source of lipase inhibitor 
 Phytochemicals from natural sources affect on various pathways which gives 
the anti-obesity effects, such as inhibition of lipase enzyme, stimulation of energy 
expenditure, suppress appetite, inhibition of adipocyte differentiation and regulation 
of lipid metabolism. There are many studies done in search for new anti-obesity 
drugs by exploiting natural products. Vast types of dietary phytochemicals such as 
flavonoids, polyphenols, saponins, tannins, alkaloids and terpenes (Table 2.1) that 
have lipase inhibitory properties are potential alternatives for obesity treatment (Ado 
et. al., 2013 and Mohamed et al., 2014).  .  
 
Table 2.1: Types of phytochemicals and classes that have anti-obesity properties (de 
la Garza et. al., 2011). 
Phytochemicals Examples of phytochemicals class 
Polyphenols Flavonoids, isoflavones, chalcones, 
phenolic acids 
Terpenoids Carotenoids, sesquiterpenes 




Various plants were widely screened for their lipase inhibitory activity in order 
to find active anti obesity agents. Natural resources can be exploited to find 
alternative for obesity treatments with a possibility of less or no side effects. Alias et. 
al. (2017) screened 24 crude plant extracts for lipase inhibitory activity with porcine 
pancreatic lipase in vitro assay. Four extracts were found to have inhibition more 
than 70 % which was considered as high activity. The most effective extract as 
pancreatic lipase inhibitor was Phyllanthus niruri with IC50 value of 27.7 µg/ml and 
followed by Orthosiphon stamineus (34.7 µg/ml), Murraya paniculata (41.5 µg/ml) 
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and Averrhoa bilimbi (55.2 µg/ml). The plant parts used were leaves, and whole 
plant for Phyllanthus niruri. However, these extracts were less potent when 
compared to orlistat which have IC50 value of 1.7 µg/ml. 
 
Ado et. al. (2013) tested 98 plants from Malaysia on pancreatic lipase to 
determine their inhibitory activity. Methanolic extracts of all plants were subjected to 
in vitro assay and 19.4 % of the extracts showed inhibition by more than 80.0 %. 
Four plants namely Aleurites moluccana L. Willd (leaves), Archidendron jiringa 
(Jack) I.C Nielsen (flowers), Averrhoa carambola L. (fruits) and Cynometra 
cauliflora L. (leaves) showed 100 % inhibition against pancreatic lipase. An isolated 
compound from Cynometra cauliflora known as kaempferol 3-O-rhamnoside was 
also determined as an active lipase inhibitor.  
 
In another study, Lee et. al. (2010) have successfully isolated new C-
glycosylated flavones known as luteolin 6-C-β-D-boivinopyranoside from 
Eremochloa ophiuroides which was predicted to be potential lipase inhibitor.  
 
Shin et. al., (2003) tested 200 herbal medicines for anti lipase activity and 
discovered that Alpinia officinarum is an effective lipase inhibitor with IC50 value of 
9.6 mg/ml. Water extract of Alpinia officinarum was tested on in vitro assay of 
pancreatic lipase and in vivo test on hyperlipidemic mice. 3-methylethergalangin was 
successfully isolated and identified as potential lipase inhibitor with IC50 of 1.3 
mg/ml. The effectiveness of this compound as lipase inhibitor was considered good 




Kim et. al., (2010) studied on inhibitory effects of ethanolic extract of Morus 
bombycis against pancreatic lipase. The root of Morus bombycis showed a good 
inhibitory effect with IC50 value of 2.07 µg/ml, even though it is less effective when 
compared to orlistat, with IC50 value of 0.154 µM. 
 
Green tea beverages that are widely consumed have shown the ability to 
inhibit pancreatic lipase by 66.5 % because of the presence of catechins in the green 
tea (Koo and Noh, 2007 and Juhel et al., 2000). Martins et. al., (2009) studied on 
inhibitory activity of mate tea, the sources of beverages that being consumed in 
Brazil. Mate tea is known to contain saponins and caffeine which have a good 
inhibition against pancreatic lipase.  
 
Kumar et. al. (2012) screened 33 Indian medicinal plants for their anti lipase 
activity. Cassia siamea roots extract is the most effective lipase inhibitor with 74.3 % 
inhibition. Cassia siamea is an edible plant and its leaves are used in making curry. 
Other plants with high inhibition activity are the leaves of Chukrasia tabularis (67.6 
%), roots of Vigna radiata (64.6 %), fruits of Lagerstroemia indica (70.1 %), whole 
plants of Justicia gendarussa (61.1 %) and resin of Ferrula asaefoetida (72.5 %).  
 
Crude extracts and isolated compounds derived from natural products have 
been documented for its ability to reduce body weight such as, 3-
Methylethergalangin (7) and 5-Hydroxy-7-(4'-hydroxy-3'methoxyphenyl)-1-phenyl-
3-heptanone (8) were isolated from Alpinia officinarum (Shin et. al., 2003 and Shin 
et. al., 2004), new isolated compound that identified as pancreatic lipase inhibitor, 3-
O-trans-p-coumaroyl actinidic acid (9) from Actinidia arguta (Jang et. al., 2008), 
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luteolin 6-C-β-D boivinopyranoside (10) from the leaves of Eremochloa ophiuroides 
(Lee et. al., 2010), cassiamin A (11) was isolated from Cassia siamea (Kumar et. al., 
2012), carpesterol (12) was isolated from fruits of Solanum stramonifolium 
(Chanmee et. al., 2013), kaempferol-3-O-rhamnoside (13) from Cynometra 
cauliflora (Ado et. al., 2013) (Figure 2.4). From previous studies, natural products 







Figure 2.4: Chemical structure of 3-methylethergalangin (7) 5-hydroxy-7-(4'-
hydroxy-3'methoxyphenyl)-1-phenyl-3-heptanone (8), 3-O-trans-p-coumaroyl 
actinidic acid (9), luteolin 6-C-β-D boivinopyranoside (10), cassiamin A (11), 




In conclusion, previous studies have showed that natural resources, especially 
those being consumed as herbal medicines, can provide an alternatives remedy in an 
attempt to control alarming statistics of obesity that continue to increase.  
 
2.4 Strategies and target protein in this study 
In this study, strategy of treatment to treat obesity was focused on one of the 
most potential and promising strategy which is inhibition of pancreatic lipase, an 
enzyme responsible for hydrolysis of dietary fat, in attempt to reduce energy intake 
through gastrointestinal mechanism, without modifying the central mechanism (Yun, 
2010). Inhibition of pancreatic lipase does not alter the central mechanism, but 
prevents any interference on central mechanism of human body. Utilization of 
natural remedies for weight loss purpose is widely used because of its reliability, cost 
and safety compared to available treatment (Kazemipoor et. al., 2012). In silico 
screening and in vitro assay approaches are employed to find potential lead for lipase 
inhibitor. 
 
2.4.1 Pancreatic lipase 
Lipase is a water soluble enzyme secreted by pancreatic acinar cells, which is 
responsible for hydrolyzing long chain substrates such as triglycerides to glycerol 
and free fatty acids as shown in Figure 2.5 (Eydoux et. al., 2008). In most of lipases, 
the active binding pocket for substrate is restrained by the so-called lid, formed by a 
surface loop. In the presence of lipase inhibitors, the lid was found to undergo 
conformational changes which lead to accessible of solvent in the active site (Eydoux 




Figure 2.5: Hydrolysis of triglyceride to produce glycerol and free fatty acids 
(Hermansyah et. al., 2007).  
 
Pancreatic lipase or also called triglyceride lipase is an important enzyme that 
needed for all aspects of fat metabolism. Of the known pancreatic lipases, pancreatic 
triglyceride lipase (PTL), the archetype of the lipase family, is clearly essential for 
the efficient digestion of dietary triglycerides. It fulfils the uptake of fats into various 
tissues, and the mobilization of fats inside cells. The correlative benefaction of 
pancreatic lipase to the substantial lipid hydrolysis is approximately 70-90 %. 
Triglyeride lipase became a key function in dietary fat absorption by hydrolyzing 
triglycerides into diglycerides and then into monoglycerides and free fatty acids 
(Winkler et. al., 1990). The hydrolysis of dietary triglycerides is critical for their 
utilization because triglycerides are not absorbed by intestinal absorptive cell. 
Dietary triglycerides must be cleaved into free fatty acids and glycerol before they 
are absorbed. In humans, triglyceride lipases are found in the gastrointestinal tract, 
bound to epithelial surfaces, and inside fat storage cells. Although some lipases will 
degrade a broad range of ester compounds, they all hydrolyze the ester bonds in 
acylglycerols, including the triglycerides that comprise greater than 95% of the 
dietary fats in the diet. Thus, inhibition of pancreatic lipase prevents the hydrolysis of 
triglyceride. The hydrolysis of dietary triglyceride is crucial for absorption and 





utilization of the free fatty acids. Inhibition of pancreatic lipase resulted in excretion 
of dietary triglycerides in the stools (Winkler et. al., 1990). 
 
The three-dimensional structures of various triglyceride lipases classes that 
reported previously are belong to a class of serine esterase. Serine in triglyceride 
lipases made up the catalytic triad that essential in hydrolyzing triglyceride. The 
active serine possessed a nucleophilic characteristic (Egloff et. al., 1995b). 
 
 Lipase has a group of amino acid that act as surface loop to prevent serine 
reaching the solvent and the loop will rearranged in the presence of substrate to make 
an entrance.  In order to investigate the rearrangement of surface loops to give access 
to catalytic triad, some researches had attempted to synthesize inhibitors that can 
mimic hydrophobicity of triglyceride. There are many small compounds synthesized 
as inhibitor for lipase. However, a phosphonate inhibitors with long alkyl chain have 





2.4.1(a)  Crystal structure of pancreatic lipase 
Crystallographic structure of pancreatic lipase that is used for computational 
simulation in this study was explained comprehensively by Egloff et. al., (1995a). A 
complex structure of pancreatic lipase was deposited in Protein Databank Website 
(www.rcsb.com), existed with covalently bounded phosphonate inhibitor and 
detergent molecules at 2.46 Å resolutions (Figure 2.6). The phosphonate inhibitor is 
methoxyundecyl phosphonate (MUP) and detergent molecules are octyl β-glucoside. 
Detergent molecules were needed for the crystallization of the protein. Visualization 
after model refinement showed that the MUP is covalently bonded to oxygen of 
Ser152 (Figure 2.7) which suggest the charactacteristic of MUP as potent inhibitor 
for pancreatic lipase. From the crystallographic structure, MUP is identified to exist 
as R and S enantiomers. These enantiomers were fitted into electron density map 
with refined partial occupancies for both enantiomers. Occupancies of R enantiomer 
have been refined to 0.65, while 0.40 for S enantiomer. These enantiomers existed in 
the active site of pancreatic lipase to mimic the alkyl chain of triglyceride. Five 
detergent molecules known as octyl β-glucoside also refined in lipase structure.  
 
The active site of lipase consists of hydrophobic groove next to the active 
serine and opposite to catalytic triad are Ser152, Asp176, and His263 (Figure 1.7). 
Since lipase catalyzes lipid, hydrophobic interaction become the major contribution 
to the free energy of binding of inhibitor. Hydrophobic interaction is important to 
maintain the conformation and stabilizes the protein. Pancreatic lipase has a lid-like 
structure which to prevent an access of substrate to the active site. However, in the 
presence of hydrocarbons molecules, the lid-like structure will undergo 




Figure 2.6: Surface representation of crystallographic structure of pancreatic 
lipase (PDB ID: 1LPB). 
 
 
Figure 2.7: The catalytic triad of pancreatic lipase comprises of Ser152, 
Asp176 and His263. 
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